Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo

Loss of Asxl1 results in myelodysplastic syndrome, whereas concomitant deletion of Tet2 restores HSC self-renewal and triggers a more severe disease phenotype distinct from that seen in single-gene knockout mice.

[1]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[2]  D. Birnbaum,et al.  Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Weissman,et al.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes , 2013, Proceedings of the National Academy of Sciences.

[4]  S. González,et al.  Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. , 2012, Cell stem cell.

[5]  Somasekar Seshagiri,et al.  Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation , 2012, Science.

[6]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Steidl,et al.  Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. , 2012, Blood.

[8]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[9]  Iannis Aifantis,et al.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.

[10]  S. Sugano,et al.  Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. , 2012, Blood.

[11]  S. Ogawa,et al.  Genome-wide analysis of myelodysplastic syndromes. , 2012, Current pharmaceutical design.

[12]  G. Scarano,et al.  Two novel patients with Bohring–Opitz syndrome caused by de novo ASXL1 mutations , 2012, American journal of medical genetics. Part A.

[13]  T. Haferlach,et al.  ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events , 2012, Genes, chromosomes & cancer.

[14]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[15]  M. Caligiuri,et al.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. , 2011, Blood.

[16]  Feng-Chun Yang,et al.  Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.

[17]  A. Jankowska,et al.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. , 2011, Blood.

[18]  K. Rajewsky,et al.  Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice , 2011, Proceedings of the National Academy of Sciences.

[19]  Patrick Callier,et al.  Germline deletion of the miR-1792 cluster causes growth and skeletal defects in humans , 2011 .

[20]  L. Vissers,et al.  De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome , 2011, Nature Genetics.

[21]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[22]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[23]  T. Suda,et al.  Faculty Opinions recommendation of A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. , 2011 .

[24]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[25]  C. Schumann,et al.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Patrick Callier,et al.  Germline deletion of the miR-17-92 cluster causes growth and skeletal defects in humans , 2011, Nature Genetics.

[27]  P. Woll,et al.  Persistent malignant stem cells in del(5q) myelodysplasia in remission. , 2010, The New England journal of medicine.

[28]  M. Cazzola,et al.  Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia , 2010, Leukemia.

[29]  J. Hess,et al.  Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. , 2010, Blood.

[30]  J. Hess,et al.  Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. , 2010, Developmental biology.

[31]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[32]  P. Aplan,et al.  Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome , 2008, Haematologica.

[33]  K. Anderson,et al.  The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. , 2007, Blood.

[34]  J. Downing,et al.  Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias , 2007, Leukemia.

[35]  Kristian Helin,et al.  The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. , 2007, Genes & development.

[36]  Christian Steidl,et al.  Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells , 2006, Nature Genetics.

[37]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Zhenhua Zhang,et al.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. , 2005, Blood.

[39]  F. Rosenbauer,et al.  Role of Transcription Factors C/EBPα and PU.1 in Normal Hematopoiesis and Leukemia , 2005, International journal of hematology.

[40]  T. Graf,et al.  Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing , 2004, Development.

[41]  J. Kutok,et al.  Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1 , 2004, Nature Genetics.

[42]  A. Yoneyama.  [Peripheral blood analysis]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[43]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[44]  Chunaram Choudhary,et al.  Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. , 2003, Blood.

[45]  D. Tenen,et al.  The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. , 2003, Blood.

[46]  John T. Dimos,et al.  A Stem Cell Molecular Signature , 2002, Science.

[47]  D. Melton,et al.  "Stemness": Transcriptional Profiling of Embryonic and Adult Stem Cells , 2002, Science.

[48]  S. Nishiguchi,et al.  Polycomb Group Gene rae28 Is Required for Sustaining Activity of Hematopoietic Stem Cells , 2002, The Journal of experimental medicine.

[49]  M. Minden,et al.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia. , 2002, Blood.

[50]  D. Gilliland.  The diverse role of the ETS family of transcription factors in cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  S. E. Jacobsen,et al.  Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. , 2000, Blood.

[52]  R. DePinho,et al.  The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus , 1999, Nature.

[53]  T. Shows,et al.  NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. , 1998, Cancer research.

[54]  F. Alt,et al.  Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M Aguet,et al.  Inducible gene targeting in mice , 1995, Science.

[56]  M. Yamaguchi,et al.  Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells. , 1995, Blood.

[57]  M. Yamaguchi,et al.  Proliferation and differentiation of myelodysplastic CD34+ cells in serum‐free medium: response to individual colony‐stimulating factors , 1993, British journal of haematology.